Contrast enhanced MR-guided biopsy of hepatocellular carcinoma.
Magnetic resonance (MR)-guided liver biopsy was performed in three patients with hepatocellular carcinoma. The tumor was considered (n = 2) or proven (n = 1) inaccessible with ultrasound or computed tomographic guidance. Because all lesions were poorly delineated on nonenhanced MR imaging, contrast agents (Gd-BOPTA, n = 1; ferucarbotran, n = 2) were applied to facilitate biopsy in an open low-field scanner. Postcontrast tumor conspicuity was fair in the patient receiving Gd-BOPTA and excellent in both patients receiving ferucarbotran, and biopsy was successful in all cases.
König
C W
CW
Department of Diagnostic Radiology, Eberhard-Karls University of Tübingen, Hoppe-Seyler-Str. 3, D-72076 Tübingen, Germany. claudius.koenig@med.uni-tuebingen.de
Trübenbach
J
J
Fritz
J
J
Lauer
U M
UM
Claussen
C D
CD
Pereira
P L
PL
D000368:Aged; D001706:Biopsy; D006528:Carcinoma, Hepatocellular / Q000473:pathology*; D003287:Contrast Media; D005682:Gadolinium; D006801:Humans; D008099:Liver / Q000473:pathology; D008113:Liver Neoplasms / Q000473:pathology*; D008279:Magnetic Resonance Imaging; D008297:Male; D008536:Meglumine / Q000031:analogs & derivatives*; D009942:Organometallic Compounds
D003287:Contrast Media; D009942:Organometallic Compounds; C064572:gadobenic acid; D008536:Meglumine; D005682:Gadolinium